<p>摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）中的持股在第四季度增长了 1,021.1%，根据该公司最近向 SEC 的披露。该公司在此期间购买了 61,174 股后，持有 67,165 股。摩根大通在 Aerovate Therapeutics 中的持股约占 0.23%，价值 178,000 美元，截止到最近的报告期末。</p>
<p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
<p>其他对冲基金和机构投资者最近也对该公司的持股进行了调整。Corient Private Wealth LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 98,000 美元。Ieq Capital LLC 在第四季度获得了 Aerovate Therapeutics 的新头寸，估计价值约为 38,000 美元。Deltec Asset Management LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 514,000 美元。FNY Investment Advisers LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 198,000 美元。最后，巴克莱 PLC 在第三季度将其在 Aerovate Therapeutics 的持股提高了 310.8%。巴克莱 PLC 现在持有该公司 18,972 股，价值 39,000 美元，此前又购买了 14,354 股。</p>
<h2>Aerovate Therapeutics 股票上涨 24.8%</h2>
<p>AVTE 股票周一开盘价为 12.48 美元。Aerovate Therapeutics, Inc.的 12 个月低点为 43.75 美元，12 个月高点为 884.98 美元。该公司的 50 日移动平均线为 82.82 美元，200 日移动平均线为 86.86 美元。公司的市值为 3.6173 亿美元，市盈率为-4.17，贝塔值为 0.95。</p>
<p>Aerovate Therapeutics（NASDAQ:AVTE - 获取免费报告）最近在 4 月 25 日星期五发布了季度财报。该公司报告每股收益为（3.15 美元），超出市场共识预期的（10.50 美元）7.35 美元。分析师平均预计 Aerovate Therapeutics, Inc.在本年度将发布-2.64 的每股收益。</p>
<h2>Aerovate Therapeutics 分红公告</h2>
<p>该公司最近还披露了一项分红，已于 4 月 28 日星期一支付。4 月 25 日的股东记录将获得 84.00 美元的分红。除息日期为 4 月 29 日星期二。</p>
<h2>关于 Aerovate Therapeutics</h2>
<p>（免费报告）</p>
<p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>何时出售股票以获利或止损</li>
<li>西部数据：存储行业是否准备反弹？</li>
<li>便士股票是否适合你的投资组合？</li>
<li>Wingstop 股票因第一季度超预期和扩张前景而上涨</li>
<li>如何捕捉分红增加的好处</li>
<li>为什么像埃克森美孚和赫斯这样的能源股票重新受到关注</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AVTE 吗？</strong> 访问 HoldingsChannel.com，获取 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
<p>在考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
<p>虽然 Aerovate Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVTE

摩根大通

<p>摩根大通（JPMorgan Chase & Co.）在 2023 年第四季度将其在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）的持股增加了 1,021.1%，目前持有 67,165 股，价值 178,000 美元。其他机构投资者也增持了该公司的股份。Aerovate 的股票上涨了 24.8%，开盘价为 12.48 美元，市值为 3.6173 亿美元。该公司报告的季度每股收益为（3.15 美元），超出预期。Aerovate 专注于开发罕见心肺疾病的治疗方案，并最近宣布派发 84.00 美元的股息</p>

<p>JPMorgan Chase &amp; Co. grew its position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report) by 1,021.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,165 shares of the company's stock after purchasing an additional 61,174 shares during the period. JPMorgan Chase &amp; Co. owned about 0.23% of Aerovate Therapeutics worth $178,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）中的持股在第四季度增长了 1,021.1%，根据该公司最近向 SEC 的披露。该公司在此期间购买了 61,174 股后，持有 67,165 股。摩根大通在 Aerovate Therapeutics 中的持股约占 0.23%，价值 178,000 美元，截止到最近的报告期末。</p>
</div><p>Get <strong>Aerovate Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aerovate Therapeutics</strong> 的提醒：</p>
</div><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in shares of Aerovate Therapeutics in the fourth quarter worth about $98,000. Ieq Capital LLC acquired a new position in shares of Aerovate Therapeutics in the 4th quarter valued at approximately $38,000. Deltec Asset Management LLC bought a new stake in Aerovate Therapeutics during the 4th quarter worth approximately $514,000. FNY Investment Advisers LLC bought a new stake in Aerovate Therapeutics during the 4th quarter worth approximately $198,000. Finally, Barclays PLC raised its holdings in Aerovate Therapeutics by 310.8% during the 3rd quarter. Barclays PLC now owns 18,972 shares of the company's stock worth $39,000 after buying an additional 14,354 shares during the period.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者最近也对该公司的持股进行了调整。Corient Private Wealth LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 98,000 美元。Ieq Capital LLC 在第四季度获得了 Aerovate Therapeutics 的新头寸，估计价值约为 38,000 美元。Deltec Asset Management LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 514,000 美元。FNY Investment Advisers LLC 在第四季度购买了 Aerovate Therapeutics 的新股份，价值约为 198,000 美元。最后，巴克莱 PLC 在第三季度将其在 Aerovate Therapeutics 的持股提高了 310.8%。巴克莱 PLC 现在持有该公司 18,972 股，价值 39,000 美元，此前又购买了 14,354 股。</p>
</div><h2>Aerovate Therapeutics Stock Up 24.8 %</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 股票上涨 24.8%</h2>
</div><p>Shares of AVTE stock opened at $12.48 on Monday. Aerovate Therapeutics, Inc. has a 12-month low of $43.75 and a 12-month high of $884.98. The firm has a fifty day moving average of $82.82 and a 200-day moving average of $86.86. The company has a market capitalization of $361.73 million, a price-to-earnings ratio of -4.17 and a beta of 0.95.</p>
<div class="lb-trans"><p>AVTE 股票周一开盘价为 12.48 美元。Aerovate Therapeutics, Inc.的 12 个月低点为 43.75 美元，12 个月高点为 884.98 美元。该公司的 50 日移动平均线为 82.82 美元，200 日移动平均线为 86.86 美元。公司的市值为 3.6173 亿美元，市盈率为-4.17，贝塔值为 0.95。</p>
</div><p>Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported ($3.15) earnings per share for the quarter, topping the consensus estimate of ($10.50) by $7.35. On average, equities analysts expect that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current year.</p>
<div class="lb-trans"><p>Aerovate Therapeutics（NASDAQ:AVTE - 获取免费报告）最近在 4 月 25 日星期五发布了季度财报。该公司报告每股收益为（3.15 美元），超出市场共识预期的（10.50 美元）7.35 美元。分析师平均预计 Aerovate Therapeutics, Inc.在本年度将发布-2.64 的每股收益。</p>
</div><h2>Aerovate Therapeutics Dividend Announcement</h2>
<div class="lb-trans"><h2>Aerovate Therapeutics 分红公告</h2>
</div><p>The firm also recently disclosed a dividend, which was paid on Monday, April 28th. Stockholders of record on Friday, April 25th were issued a $84.00 dividend. The ex-dividend date was Tuesday, April 29th.</p>
<div class="lb-trans"><p>该公司最近还披露了一项分红，已于 4 月 28 日星期一支付。4 月 25 日的股东记录将获得 84.00 美元的分红。除息日期为 4 月 29 日星期二。</p>
</div><h2>About Aerovate Therapeutics</h2>
<div class="lb-trans"><h2>关于 Aerovate Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.</p>
<div class="lb-trans"><p>Aerovate Therapeutics, Inc.是一家临床阶段的生物制药公司，开发能够改善美国罕见心肺疾病患者生活的药物。它专注于推进 AV-101，这是一种用于治疗肺动脉高压的干粉吸入剂，目前处于 2b/3 期临床试验中。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Aerovate Therapeutics</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Western Digital: Is the Storage Sector Set for a Rebound?</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Wingstop Stock Jumps on Q1 Beat, Expansion Outlook</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Why Energy Stocks Like Exxon and Hess Are Back in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aerovate Therapeutics</li>
<li>何时出售股票以获利或止损</li>
<li>西部数据：存储行业是否准备反弹？</li>
<li>便士股票是否适合你的投资组合？</li>
<li>Wingstop 股票因第一季度超预期和扩张前景而上涨</li>
<li>如何捕捉分红增加的好处</li>
<li>为什么像埃克森美孚和赫斯这样的能源股票重新受到关注</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AVTE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AVTE 吗？</strong> 访问 HoldingsChannel.com，获取 Aerovate Therapeutics, Inc.（NASDAQ:AVTE - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZURQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Aerovate Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aerovate Therapeutics 吗？</h2>
</div><p>Before you consider Aerovate Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aerovate Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Aerovate Therapeutics 并不在名单上。</p>
</div><p>While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aerovate Therapeutics 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通在 Aerovate Therapeutics, Inc.（NASDAQ:AVTE）拥有 178,000 美元的持仓